The Scientific Consultants listed below are affiliated with the Company through various
proprietary interests. They are working under contract with TBP Pharma.
Professor Dr. Andreas Hirsch
Dr. Hirsch is a world leader in fullerene chemistry. Since October 1995, he has been chaired Full Professor of Organic Chemistry at the University of Erlangen-Nürnberg. In 2004 he became Adjunct Professor at Rice University in Houston. Dr. Hirsch’s laboratory is at the forefront of carbon allotrope chemistry and he is well known for the investigations of basic principles for the functionalization of the 0-dimensional fullerenes, the 1-dimensional carbon nanotubes and the 2-dimensional graphene, which lead to synthesis of numerous examples of derivatives with tailor made structural-, electronic-, photophysical- and biomedical properties.
Dr. Hirsch received his Ph.D. in 1990 from the University of Tübingen. From 1990 to 1991 he was a postdoctoral fellow at the Institute for Polymers and Organic Solids in Santa Barbara, California in the group of Prof. Wudl. He subsequently returned to Tübingen as a research associate at the Institute for Organic Chemistry. Upon receiving his Dr. Habilitus in 1994, for which he was honored with a variety of prizes and awards including the Otto -Röhm Research Award (1994) and the ADUC Award für Habilitanden (1994) he joined the Chemistry Faculty at the University of Karlsruhe as a Professor of Organic Chemistry. He was Visiting Professor at the University of Nikosia in Cyprus (2006) and the University of Padova in Italy (2011). He is coordinator of the Graduate School Molecular Science (GSMS), the Interdisciplinary Center for Molecular Materials (ICMM) and the Collaborative Research Center “Synthetic Carbon Allotropes” (SFB 953) in Erlangen. He is on the Board of Directors of the Cluster of Excellence “Engineering of Advanced Materials” (EAM) in Erlangen and the Central Institute for Materials and Processes (ZMP) in Fürth. In 2006 he received the Elhuyar-Goldschmidt-Prize of the Spanish and German Chemical Societies. In 2007 he was elected Professor of the Year (Unicum, Beruf, Germany). In 2010 he received an ERC Advanced Grant and in 2012 he received the Max Grundig Award and the Medal of the Organic Institute of the Academy of Sciences of the Czech Republic.
Dr. Uwe Reuther, Ph.D
Dr. Reuther, a former doctoral candidate of Dr. Hirsch, has been advising TBP on processing and manufacturing improvements. He is an expert in the evaluation of synthetic pathways for the heterofullene C58N2 and pioneered the introduction of the first concept for a completely regioselective control of multiple adduct formation of C60. He is advising TBP in the commercial development of macrocyclic methods of manufacturing C3, which he invented.
Dr. Reuther received his Ph.D. in _____ from the University of Erlangen-Nürnberg.
Dr. Robert Lenk, Ph.D.
Dr. Lenk has extensive experience with successful pharmaceutical startups. He is a veteran of five start-up biopharmaceutical companies and three IPOs. He was President of the Nano-works division of Luna U.S. and he held senior leadership positions at MediVector, Luna Innovations, Therapeutics 2000 and Argus Pharmaceuticals. Dr. Lenk was a founding Scientist with the Liposome Company.
Dr. Lenk has his BSc and Ph.D. in cell biology from MIT. He holds 18 issued US patents and has authored 20 articles that have appeared in peer reviewed journals.
Dr. M. F. Beal, M.D.
Dr. Beal is an internationally recognized authority on neurodegenerative disorders. He is the Anne Parrish Titzell Professor and Chairman of the Department of Neurology and Neuroscience at the Weill Medical College of Cornell University as well as Director of the Neurology service at the New York Presbyterian Cornell Campus.
Dr. Allan Butterfield, Ph.D.
Dr. Butterfield is an endowed professor of biological chemistry at the University of Kentucky and the author of 434 publications on oxidative stress and neuro-degenerative diseases.
His laboratory studies free radical oxidative stress in aging and age-related neurodegenerative disorders, particularly Alzheimer’s disease (AD). His group first described how oxidative stress associated with amyloid β-peptide, a 42-amino acid peptide deposited in AD brains, leads to neurotoxicity and how various antioxidants can modulate or prevent this oxidative stress and neuronal death.